Showing 4431-4440 of 10240 results for "".
- Soligenix's Phase 3 FLASH Study Continues to Demonstrate Positive Benefits of SGX301 in Cutaneous T-Cell Lymphoma Patientshttps://practicaldermatology.com/news/soligenixs-phase-3-flash-study-continues-to-demonstrate-positive-benefits-of-sgx301-in-cutaneous-t-cell-lymphoma-patients/2460576/Continued optional treatment with Soligenix, Inc.’s SGX301 (synthetic hypericin) demonstrates positive benefits in patients with cutaneous T-Cell lymphoma Nearly half of all patients in Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial conti
- DermOQ To Buy Skin Products's ECHO2 Plus Oxygen Facial Treatment Product Linehttps://practicaldermatology.com/news/dermoq-to-buy-skin-products-incs-echo2-plus-oxygen-facial-treatment-product-line/2460569/DermOQ Inc. is purchasing Skin Products Inc.’s ECHO2 Plus and Oxyceuticals oxygen facial treatment product lines. DermOQ offers its topical oxygen products under the brand names DermOQ Oxygen Lab and
- Kerecis Scores DoD Grant to Develop, Test New Fish-skin Wound Treatment for Soldiershttps://practicaldermatology.com/news/kerecis-scores-dod-grant-to-develop-test-new-fish-skin-wound-treatment-for-soldiers/2460561/The U.S. Department of Defense (DoD) awarded a grant of almost $600,000 to Kerecis to test the company’s fish-skin technology to better stabilize battlefield wounds and provide a bacterial barrier for them during evacuation. The grant money will be disbursed to Kerecis over
- SkinCeuticals, Aesthetics Biomedical Join Forces for Vivace Experience Featuring SkinCeuticals C E Ferulichttps://practicaldermatology.com/news/skinceuticals-aesthetics-biomedical-join-forces-for-vivace-experience-featuring-skinceuticals-c-e-ferulic/2460558/SkinCeuticals is teaming up Aesthetics Biomedical’s Vivace Fractional Micro Needle Radio Frequency Treatment to create the professional Vivace Experience featuring SkinCeuticals C E Ferulic MaryAnn Guerra, CEO & President of Aesthetics Biomedical states, "Aesth
- Clearasil Steps Up to End Bullying, Support Skin Positivityhttps://practicaldermatology.com/news/clearasil-steps-up-to-end-bullying-support-skin-positivity/2460543/Clearasil is donating $25,000 to STOMP Out Bullying for National Bullying Prevention Month. As part of the partnership, Clearasil is also using its national platform to further the reach and impact of STOMP Out Bullying's efforts by sharing toolkits and educational resources wi
- Forte Biosciences, Inc. Announces First Patient Dosed in Study of FB-401 for the Treatment of Children and Adults With ADhttps://practicaldermatology.com/news/forte-biosciences-inc-announces-first-patient-dosed-in-study-of-fb-401-for-the-treatment-of-children-and-adults-with-ad/2460541/The first patient has been dosed in Forte Biosciences, Inc.’s clinical trial of FB-401 for the treatment of atopic dermatitis (AD). The multi-center, placebo controlled clinical trial of FB-401 is expected to enroll approximately 124 pediatric, adolescent and adult subjects aged 2
- Dr. Rafael Sierra is Cynosure's Newest R&D Advisorhttps://practicaldermatology.com/news/dr-rafael-sierra-is-cynosures-newest-rd-advisor/2460533/Rafael Sierra, PhD is back at Cynosure. The former Chief Technology Officer is now an R&D Advisor. "Dr. Sierra's passion for the science behind medical aesthetics and inherent knowledge of its clinical application are unparalleled," says Todd
- ISDIN Sunscreen Survey: Just 37% of the US Population Protects Themselves from the Sun on a Daily Basishttps://practicaldermatology.com/news/isdin-sunscreen-survey-just-37-of-the-us-population-protects-themselves-from-the-sun-on-a-daily-basis/2460505/While half of the US population is aware of the importance of sun protection and state they use sun protection during sun exposure, only 37 percent are using it on a daily basis, according to new survey from ISDIN. In the s
- AmorePacific Launches New Woke Skincare Brandhttps://practicaldermatology.com/news/amorepacific-launches-new-woke-skincare-brand/2460503/South Korea’s Amorepacific is launching its newest vegan-friendly lifestyle brand: Enough Project. This new brand is vegan-friendly, involves no animal testing, and contains no animal ingredients. In addition, Enough
- Third Pivotal Phase 3 Study Shows Rinvoq Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitishttps://practicaldermatology.com/news/third-pivotal-phase-3-study-shows-rinvoq-plus-topical-corticosteroids-improves-skin-and-itch-symptoms-in-atopic-dermatitis/2460489/AbbVie's upadacitinib (15 mg and 30 mg, once daily) (Rinvoq) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in AD Up, the third pivotal Phase 3 study of Rinvoq in atopic dermatitis. AD Up evaluated the efficacy and safety of both doses of upadaciti